Gynecologic oncology
-
Gynecologic oncology · May 2002
Multicenter Study Clinical TrialFirst-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Carboplatin and paclitaxel can be applied safely and effectively as single agents for the treatment of ovarian cancer on a weekly basis. A multicenter, phase-I study was conducted to investigate the maximum tolerated dose of a weekly combination regimen. ⋯ Weekly carboplatin and paclitaxel is a well-tolerated combination regimen in patients with primary, advanced ovarian cancer. The recommended dose for a phase II study is carboplatin at 100 mg/m(2) and carboplatin at area under the curve 2.0.